EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort

Jesús Argente, Andrea M Haqq, Jan Luca Schorfheide, Nicolas Touchot, Caroline Huber, Urs Wiedemann, Jeremy Pomeroy, Phase 3 BBS Trial Investigators

Obesity · 2026

DOI: 10.1002/oby.70125 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Obesity, 2026. Verfasst von Jesús Argente und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Pediatric Endocrinology, University Hospital Niño Jesús, Research Institute La Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Bardet-Biedl Syndrome, alpha-MSH, Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rhythm Pharmaceuticals, Inc., Bardet Biedl Syndrome Foundation and Family Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS).

Methods

Patients with BBS ≥ 6 years of age ( n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity‐score matched external control cohort ( n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3‐point decrease in BMI z ‐score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z ‐score, and body weight.

Results

A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls ( p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% ( p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings.

Conclusions

This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS. Trial Registration: ClinicalTrials.gov identifier: NCT03746522

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bardet-Biedl Syndromealpha-MSHObesityHumansFemaleMaleChildRegistriesBody Mass IndexTreatment OutcomeAdolescentAdultWeight LossYoung Adult

Stichwörter der Autor:innen

Bardet‐Biedl syndromeindirect treatment comparisonssetmelanotideweight outcomes

Substanzen

alpha-MSHsetmelanotide

Autor:innen und Institutionen

  • Department of Pediatrics and Pediatric Endocrinology, University Hospital Niño Jesús, Research Institute La Princesa, Madrid, Spain.
  • Department of Pediatrics, Universidad Autónoma de Madrid, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
  • IMDEA, Food Institute, Campus of International Excellence Universidad Autónoma de Madrid (CEIUAM) + Spanish National Research Council (CSIC), Madrid, Spain.
  • Division of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
  • stradoo Gmbh, Munich, Germany.

Förderung

  • Rhythm Pharmaceuticals, Inc.
  • Bardet Biedl Syndrome Foundation and Family Association

Zitieren

APA

Argente, J., Haqq, A. M., Schorfheide, J. L., Touchot, N., Huber, C., Wiedemann, U., Pomeroy, J., & Phase 3 BBS Trial Investigators (2026). Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity. https://doi.org/10.1002/oby.70125

Vancouver

Argente J, Haqq AM, Schorfheide JL, Touchot N, Huber C, Wiedemann U, et al. Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity. 2026. doi:10.1002/oby.70125

BibTeX
@article{Argente2026,
  author = {Argente, Jesús and Haqq, Andrea M and Schorfheide, Jan Luca and Touchot, Nicolas and Huber, Caroline and Wiedemann, Urs and Pomeroy, Jeremy and Phase 3 BBS Trial Investigators, Phase 3 BBS Trial Investigators},
  title = {Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70125}
}
Kostenlos starten →